Earnings History Data for CTI BioPharma Corp. (CTIC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2022	AH	4:05 PM ET (Nov 7)	CTIC	CTI BioPharma Corp.	574.21	-0.13	-0.15	-0.26	CTI BioPharma GAAP EPS of -$0.13 beats by $0.03, revenue of $18.2M beats by $1.03M [11/7/2022 4:10 PM]	5.82	0.85 (17.09%)	5.30	0.33 (6.64%)	1.43 - 7.80	6,930,257	3,400,000	98,309
CTI BioPharma GAAP EPS of -$0.13 beats by $0.03, revenue of $18.2M beats by $1.03M [11/7/2022 4:10 PM] CTI Biopharma surges 17% higher on Q3 earnings beat [11/8/2022 12:47 PM] CTI BioPharma Reports Third Quarter 2022 Financial Results [Nov-07-22 04:05PM] CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates [Nov-07-22 06:05PM]
08-08-2022	AH	4:05 PM ET (Aug 8)	CTIC	CTI BioPharma Corp.	643.99	-0.21	-0.20	-0.21	CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M [8/8/2022 4:14 PM]	6.26	-0.80 (-11.33%)	6.53	-0.53 (-7.51%)	1.43 - 7.80	18,716,368	3,620,000	171,235
CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M [8/8/2022 4:14 PM] CTI BioPharma Reports Second Quarter 2022 Financial Results [Aug-08-22 04:05PM]
12-05-2022	AH	4:00 PM ET (May 12)	CTIC	CTI BioPharma Corp.	399.03	-0.37	-0.34	-0.23	CTI BioPharma GAAP EPS of -$0.37 beats by $0.04, revenue of $2.3M beats by $0.76M [5/12/2022 4:08 PM]	4.29	0.63 (17.08%)	3.95	0.29 (7.92%)	1.43 - 5.76	6,672,215	3,550,000	72,231
CTI BioPharma GAAP EPS of -$0.37 beats by $0.04, revenue of $2.3M beats by $0.76M [5/12/2022 4:08 PM] CTI BioPharma Reports First Quarter 2022 Financial Results [May-12-22 04:05PM] CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates [May-12-22 05:45PM] Why CTI Biopharma Stock Is Surging Today [May-13-22 12:19PM]
31-03-2022	AH		CTIC	CTI BioPharma Corp.	472.83	-0.38	-0.28	-0.20	CTI BioPharma GAAP EPS of -$0.38 [3/31/2022 4:37 PM]	4.33	-0.34 (-7.28%)	4.55	-0.12 (-2.57%)	1.43 - 5.25	5,663,625	3,660,000	89,440
CTI BioPharma GAAP EPS of -$0.38 [3/31/2022 4:37 PM] CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates [Mar-31-22 05:15PM] CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results [Mar-31-22 04:01PM]
05-08-2021	AH	4:05 PM ET (Aug 5)	CTIC	CTI BioPharma Corp.	226.68	-0.21	-0.20	-0.19	CTI BioPharma EPS in-line [8/5/2021 4:44 PM]	2.79	0.26 (10.28%)	2.66	0.13 (5.14%)	0.96 - 4.13	1,557,847	370,000	11,876
CTI BioPharma Reports Second Quarter 2021 Financial Results [Aug-05-21 04:05PM]
01-06-2021	AH	4:05 PM ET (Jun 1)	CTIC	CTI BioPharma Corp.	223.88	-0.23	-0.20	-0.20	CTI BioPharma EPS misses by $0.02 [6/1/2021 4:15 PM]	2.40	-0.10 (-4.00%)	2.50	0.0 (0.00%)	0.96 - 4.13	1,590,577	750,000	31,754
FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA [6/1/2021 8:35 AM] CTI BioPharma EPS misses by $0.02 [6/1/2021 4:15 PM] CTI Biopharma net loss widens on R&D expenses, preparations for drug launch [6/1/2021 4:47 PM] CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis [Jun-01-21 07:00AM] CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer [Jun-01-21 09:33AM] CTI BioPharma Reports First Quarter 2021 Financial Results [Jun-01-21 04:05PM] CTI BioPharma (CTIC) Q1 2021 Earnings Call Transcript [Jun-02-21 12:00AM]
17-03-2021	AH	4:05 PM ET (Mar 17)	CTIC	CTI BioPharma Corp.	250.19	-0.20	-0.16	-0.14	CTI BioPharma EPS misses by $0.04 [3/17/2021 4:13 PM]	3.26	-0.04 (-1.36%)	3.16	-0.14 (-4.24%)	0.69 - 4.03	449,226	430,000	2,350
CTI BioPharma EPS misses by $0.04 [3/17/2021 4:13 PM] CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results [Mar-17-21 04:05PM]
10-11-2020	AH	4:05 PM ET (Nov 10)	CTIC	CTI BioPharma Corp.	243.27	-0.15	0.00	-0.17	CTI BioPharma EPS in-line [11/10/2020 4:09 PM]	3.34	0.03 (0.91%)	3.30	-0.01 (-0.30%)	0.62 - 3.68	511,530	504,217	1,427